טוען...
Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by K(ATP) channel overactivity
Cantu syndrome (CS) is a complex disorder caused by gain-of-function (GoF) mutations in ABCC9 and KCNJ8, which encode the SUR2 and Kir6.1 subunits, respectively, of vascular smooth muscle (VSM) K(ATP) channels. CS includes dilated vasculature, marked cardiac hypertrophy, and other cardiovascular abn...
שמור ב:
| הוצא לאור ב: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society for Clinical Investigation
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7269588/ https://ncbi.nlm.nih.gov/pubmed/31821173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI130571 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|